SCHEMBL6174259

SCHEMBL6174259

COC(=O)/C(=C/C1CCCCC1)c1ccc(-n2nnnc2C(F)(F)F)c(Cl)c1

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SMURF1 Q9HCE7 3/20 0.35
TACR1 P25103 11/20 0.34
GCK P35557 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6174270 1.00 SMURF1 (0.35) SMURF1TACR1GCK
SCHEMBL6173281 0.89 SMURF1 (0.32) SMURF1
SCHEMBL6173284 0.89 SMURF1 (0.32) SMURF1
SCHEMBL6174652 0.88 SMURF1 (0.38) SMURF1GCK
SCHEMBL6176395 0.88 SMURF1 (0.38) SMURF1GCK
SCHEMBL6176390 0.88 SMURF1 (0.38) SMURF1GCK
SCHEMBL6174657 0.88 SMURF1 (0.38) SMURF1GCK
SCHEMBL6173431 0.87 SMURF1 (0.36) SMURF1GCK
SCHEMBL6173423 0.87 SMURF1 (0.36) SMURF1GCK
SCHEMBL2663533 0.81 GCK (0.43) GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1311504-B1 TETRAZOLYL-PHENYL ACETAMIDE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-06-15 EP disclosed
US-6441180-B1 TO INCREASE INSULIN SECRETION, WHICH MAKES THEM USEFUL FOR TREATING TYPE II DIABETES HOFFMANN-LA ROCHE INC. 2002-08-27 US disclosed
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-05-30 US disclosed
US-6388088-B1 ANTIDIABETIC AGENTS HOFFMAN-LA ROCHE INC. 2002-05-14 US disclosed
US-6369232-B1 ANTIDIABETIC AGENTS HOFFMANN-LA ROCHE INC. 2002-04-09 US disclosed
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 US disclosed
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators SIDDURI ACHYUTHARAO (US) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035267-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 SMURF1 4717/4885TACR1 4487/4885GCK 2/4885
US-20020035266-A1 Tetrazolyl-phenyl acetamide glucokinase activators GCKR, GCK, PCK1 SMURF1 4717/4885TACR1 4487/4885GCK 2/4885
US-20020065275-A1 Tetrazolyl-phenyl actamide glucokinase activators GCKR, GCK, PFKL SMURF1 4519/4885TACR1 4457/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.